世卫组织发布新型减肥药物使用指南

Core Insights - The World Health Organization (WHO) has released its first guidelines on the use of new weight loss medications, recognizing obesity as a chronic disease requiring comprehensive lifelong care [1][2] - Over 1 billion people globally suffer from obesity, with an estimated 3.7 million related deaths projected for 2024, highlighting the urgent need for effective health policies [1] - WHO estimates that without strong measures, the number of people affected by obesity could double by 2030, leading to a $3 trillion annual economic loss [1] Group 1 - The new guidelines focus on GLP-1 (glucagon-like peptide-1) medications, such as liraglutide, semaglutide, and terzepatide, recommending their conditional use as a long-term treatment option for obesity [1][2] - GLP-1 therapy mimics natural hormones to regulate appetite, blood sugar, and digestion, aiding obese patients in weight loss and improving health indicators [2] - The guidelines suggest that these medications should be used in conjunction with other supportive measures, including healthy eating, increased physical activity, and long-term professional guidance for optimal effectiveness [2] Group 2 - WHO emphasizes that the long-term safety evidence for these medications is limited, and there are uncertainties regarding weight maintenance after discontinuation, along with high costs associated with these treatments [2] - The guidelines recommend the long-term use of GLP-1 medications for adult obesity patients, excluding those who are pregnant [2]